Secura Bio
NV - Las VegasBiotechnology
Focus: Secura Bio is a Las Vegas-based public biotech focused on acquiring and commercializing oncology assets worldwide, with a highly concentrated revenue base dependent on a single marketed drug.
Profile data last refreshed 12h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
4-1 this month
Stable — net -1 jobs in 30d
1 added, 2 removed. Backfill posture.
Should You Work at Secura Bio?
AI assessmentSuitable for risk-tolerant candidates seeking stable commercial oncology roles, but limited growth potential and pipeline traction make this a consolidation/harvesting play rather than a growth engine.
Why Work Here
- COPIKTRA (duvelisib) in peak lifecycle with LOE protection until 2035 provides commercial stability and revenue visibility for oncology roles
Data completeness
6/9 — Partial
Company HealthSolid
Pipeline
Early-stage
10 total
LOE Risk
1 imminent
FARYDAK
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$21M Part DStable
Peak8.5yr
Sole revenue driver with 9-year patent runway; PI3K-δ/γ inhibitor targeting B-cell receptor signaling in CLL and lymphomas.
Help build intelligence for Secura Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.